Skip to main content

Genetic Testing Market 2024

Genetic Testing Market 2024 Size, Share, Industry, Forecast to 2030


The Genetic Testing Market 2024 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Genetic Testing market. This report explores all the key factors affecting the growth of the global Genetic Testing market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

Genetic Testing Market Segmentation are:

by Type (Predictive Testing, Carrier Testing, Prenatal & Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, and Others), Technology (Cytogenetic Testing, Biochemical Testing, and Molecular Testing), and Application (Chromosome Analysis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, and Others)

Genetic Testing Market 2023 Overview:

The global genetic testing market was valued at $7,501.90 million in 2017 and is projected to reach $17,606.70 million by 2025, growing at a CAGR of 11.3% from 2018 to 2025.

Genetic testing is the study of DNA that identifies gene mutation associated with a variety of genetic disorder. There are various types of genetic testing, and several methods such as cytogenetic testing, biochemical testing, molecular testing, molecular testing, and chromosome analysis are used to determine the changes in persons chromosomes, genes, or proteins. The outcomes of a genetic test confirm or diagnose a suspected genetic condition or help determine a persons chance of developing or passing on a genetic disorder.

The global genetic testing market is expected to register substantial growth in the near future, owing to rise in incidence of genetic disorders & cancer and growth in awareness & acceptance of personalized medicines. In addition, advancements in genetic testing techniques are expected to boost the market growth during the forecast period. However, standardization concerns of genetic testing-based diagnostics and stringent regulatory requirements for product approvals are anticipated to hamper the market growth during the forecast period. Conversely, untapped emerging markets in developing countries are expected to provide remunerative opportunities for the market players.

The global genetic testing market is segmented based on type, technology, application, and region. By type, the market is categorized into predictive testing, predictive testing, prenatal & newborn testing, diagnostic testing, pharmacogenomic testing, and others. On the basis of technology, the market is divided into cytogenetic testing, molecular testing, and DNA sequencing. By application, it is segmented into cancer diagnosis, genetic disease diagnosis, cardiovascular disease diagnosis, and others. Region wise, the market analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Genetic testing, DNA analysis, precision medicine, genomics, hereditary diseases, genetic counseling, pharmacogenomics, ancestry testing, molecular diagnostics, next-generation sequencing (NGS), genetic screening, personalized medicine, direct-to-consumer genetic testing, genetic biomarkers, cancer genomics, prenatal genetic testing, rare disease diagnostics, carrier screening, genetic risk assessment, clinical genetics.

#GeneticTesting, #Genomics, #DNAAnalysis, #PrecisionMedicine, #HereditaryDiseases, #GeneticCounseling, #Pharmacogenomics, #AncestryTesting, #MolecularDiagnostics, #NextGenSequencing, #GeneticScreening, #PersonalizedMedicine, #DirectToConsumerTesting, #GeneticBiomarkers, #CancerGenomics, #PrenatalTesting, #RareDisease, #CarrierScreening, #RiskAssessment, #ClinicalGenetics.

Comments

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...

Genetic Test

Genetic test eliminates progressive retinal atrophy in English shepherd dogs Researchers at the University of Cambridge recently published their findings in Genes after identifying the genetic mutation that is causing progressive retinal atrophy (PRA) in English shepherd dogs. PRA is a group of inherited diseases causing progressive degeneration of the light sensitive cells within the back of the eyes. When it comes to PRA in dogs, they are born with normal vision but by the age of 4-5 they go totally blind with no treatment. According to the release, by identifying the canines carrying this disease before they lose vision, this can be then used as a tool to guide breeding decisions to prevent the passing of the disease onto puppies.1 Historically, owners did not realize their dog had PRA until they were middle-aged, which means it could have been passed on to puppies if they had bred, making this a hard disease to control. “Once the dog’s eyesight starts to fail there’s no treatment ...